Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
For many investors, the experimental psychedelics industry may be too risky to invest in. Most companies in this sector are privately held, and psychedelic stocks are often volatile penny or OTC stocks.Aside from being risky, these stocks can also be difficult to purchase. Most stocks will require you to have a brokerage account that offers access to OTC and international stocks, like Interactive Brokers or TradeStation.
For investors willing to take the risk, the best psychedelic stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation, which is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
COMPASS Pathways stock opened the day at $40.90 after a previous close of $39.02. The latest price was $41.21 (25 minute delay). COMPASS Pathways is listed on the NASDAQ.
Mind Medicine (MindMed) Inc. , a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.
Mind Medicine MindMed stock opened the day at $2.34 after a previous close of $2.34. The latest price was $2.24 (25 minute delay). Mind Medicine MindMed is listed on the OTCQB and employs 22 staff.
Mycotopia Therapies Inc. provides psychedelic therapies through technology-focused, data-driven, and medical-based solutions for people dealing with anxiety, depression, bipolar disorders, PTSD, ADHD, autism, and addictions. The company was incorporated in 2019 and is based in Aventura, Florida.
20/20 Global stock opened the day at $3.50 after a previous close of $3.50. The latest price was $3.50 (25 minute delay). 20/20 Global is listed on the PINK.
Numinus Wellness Inc. provides solutions to develop and deliver psychedelic-assisted psychotherapy and transform the mental health landscape. The company operates in two divisions, Salvation Botanicals and Numinus Health.
Numinus Wellness stock opened the day at C$0.86 after a previous close of C$0.90. The latest price was C$0.83 (25 minute delay). Numinus Wellness is listed on the V and has a trailing 12-month revenue of around CAD$975,951. All prices are listed in Canadian Dollars.
Mindset Pharma Inc. operates as a neuro-pharmaceutical drug discovery and development platform company. It offers psychedelic compounds for treatment-resistant neurological and psychiatric disorders.
The latest price was C$0.51 (25 minute delay). Mindset Pharma is listed on the CN. All prices are listed in Canadian Dollars.
Cybin Inc. , a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey.
Cybin stock opened the day at $1.23 after a previous close of $1.35. The latest price was $1.17 (25 minute delay). Cybin is listed on the OTCQB and employs 6 staff.
Field Trip Health Ltd. engages in the development and delivery of psychedelic therapies. Its Research division is involved in the development of psychedelic molecules and conducting research on plant-based psychedelics.
The latest price was C$5.75 (25 minute delay). Field Trip Health is listed on the CN and has a trailing 12-month revenue of around CAD$435,460. All prices are listed in Canadian Dollars.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.